Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENLVNASDAQ:ENSCNASDAQ:MIRANASDAQ:QTTB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENLVEnlivex Therapeutics$1.09+4.3%$0.98$0.81▼$1.76$24.72M0.74127,339 shs139,267 shsENSCEnsysce Biosciences$2.02-5.2%$2.31$1.62▼$14.67$5.05M0.97945,159 shs42,900 shsMIRAMIRA Pharmaceuticals$1.22-0.8%$1.20$0.51▼$5.01$20.81M1.962.20 million shs84,335 shsQTTBQ32 Bio$1.55-2.8%$1.74$1.38▼$53.79$19.45M-0.03200,251 shs84,442 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENLVEnlivex Therapeutics+4.31%+20.44%+11.28%+4.31%-15.50%ENSCEnsysce Biosciences-5.16%-2.42%-9.42%-41.45%-75.61%MIRAMIRA Pharmaceuticals-0.81%+0.83%+0.83%-4.69%+71.83%QTTBQ32 Bio-2.82%-7.19%-6.63%-25.12%-91.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENLVEnlivex Therapeutics2.6366 of 5 stars3.75.00.00.00.60.80.6ENSCEnsysce Biosciences0.2707 of 5 stars0.04.00.00.00.00.00.6MIRAMIRA Pharmaceuticals2.3884 of 5 stars3.75.00.00.00.60.00.6QTTBQ32 Bio2.9095 of 5 stars3.14.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENLVEnlivex Therapeutics 3.33Buy$10.00817.43% UpsideENSCEnsysce Biosciences 0.00N/AN/AN/AMIRAMIRA Pharmaceuticals 3.33Buy$14.001,047.54% UpsideQTTBQ32 Bio 2.25Hold$12.17684.95% UpsideCurrent Analyst Ratings BreakdownLatest ENSC, ENLV, QTTB, and MIRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/3/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.003/24/2025ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.00 per shareN/AENSCEnsysce Biosciences$5.21M0.92N/AN/A$2.59 per share0.78MIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.13 per shareN/AQTTBQ32 Bio$1.16M16.30N/AN/A$0.47 per share3.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENLVEnlivex Therapeutics-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)ENSCEnsysce Biosciences-$7.99M-$6.54N/AN/AN/A-109.49%-192.54%-121.77%8/13/2025 (Estimated)MIRAMIRA Pharmaceuticals-$7.85M-$0.51N/AN/AN/AN/A-341.08%-272.93%8/12/2025 (Estimated)QTTBQ32 Bio-$47.73M-$4.94N/AN/AN/AN/A-447.33%-59.77%8/6/2025 (Estimated)Latest ENSC, ENLV, QTTB, and MIRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q1 2025ENLVEnlivex Therapeutics-$0.16-$0.15+$0.01-$0.15N/AN/A5/14/2025Q1 2025MIRAMIRA Pharmaceuticals-$0.15-$0.11+$0.04-$0.11N/AN/A5/13/2025Q1 2025ENSCEnsysce Biosciences-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 million5/8/2025Q1 2025QTTBQ32 Bio-$1.23-$0.90+$0.33-$0.90N/AN/A3/31/2025Q4 2024ENLVEnlivex Therapeutics-$0.16-$0.23-$0.07-$0.23N/AN/A3/28/2025Q4 2024MIRAMIRA Pharmaceuticals-$0.29-$0.15+$0.14-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENLVEnlivex TherapeuticsN/A7.207.20ENSCEnsysce BiosciencesN/A2.502.50MIRAMIRA PharmaceuticalsN/A12.8612.86QTTBQ32 Bio1.684.714.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENLVEnlivex Therapeutics1.02%ENSCEnsysce Biosciences5.63%MIRAMIRA Pharmaceuticals35.16%QTTBQ32 Bio31.32%Insider OwnershipCompanyInsider OwnershipENLVEnlivex Therapeutics12.28%ENSCEnsysce Biosciences7.90%MIRAMIRA Pharmaceuticals6.65%QTTBQ32 Bio40.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENLVEnlivex Therapeutics7023.65 million20.75 millionOptionableENSCEnsysce Biosciences102.37 million2.18 millionNot OptionableMIRAMIRA Pharmaceuticals216.92 million15.80 millionNot OptionableQTTBQ32 Bio3912.20 million7.32 millionN/AENSC, ENLV, QTTB, and MIRA HeadlinesRecent News About These CompaniesQ32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | prnewswire.comQ32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia AreataApril 30, 2025 | prnewswire.comLeerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)April 18, 2025 | markets.businessinsider.comQ32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia AreataApril 16, 2025 | prnewswire.comAll You Need to Know About Q32 Bio (QTTB) Rating Upgrade to BuyApril 8, 2025 | zacks.comAnalysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Q32 Bio (QTTB)March 12, 2025 | markets.businessinsider.comQ32 Bio price target lowered to $15 from $16 at Wells FargoMarch 12, 2025 | markets.businessinsider.comQ32 Bio Reports Promising Trial Results and FinancialsMarch 12, 2025 | tipranks.comQ32 Bio: Q4 Earnings SnapshotMarch 11, 2025 | sfgate.comQ32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate UpdateMarch 11, 2025 | prnewswire.comQ32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibartMarch 10, 2025 | markets.businessinsider.comQ32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology MeetingMarch 8, 2025 | prnewswire.comQ32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual MeetingFebruary 28, 2025 | prnewswire.comQ32 Bio to Participate in Upcoming March Investor ConferencesFebruary 26, 2025 | prnewswire.comPiper Sandler Downgrades Q32 Bio (QTTB)February 12, 2025 | msn.comBMO Capital Downgrades Q32 Bio (QTTB)February 12, 2025 | msn.comQ32 Bio (NASDAQ:QTTB) Stock Quotes, Forecast and News SummaryFebruary 12, 2025 | benzinga.comQ32 Bio sticks with bempikibart, but loses staff and phase 2 complement inhibitorFebruary 11, 2025 | fiercebiotech.comPiper Sandler cuts Q32 Bio stock rating to neutral, slashes targetFebruary 11, 2025 | msn.comQ32 Bio downgraded to Neutral from Overweight at Piper SandlerFebruary 11, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENSC, ENLV, QTTB, and MIRA Company DescriptionsEnlivex Therapeutics NASDAQ:ENLV$1.09 +0.05 (+4.31%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.10 +0.00 (+0.46%) As of 06/20/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Ensysce Biosciences NASDAQ:ENSC$2.02 -0.11 (-5.16%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.09 +0.07 (+3.47%) As of 06/20/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.MIRA Pharmaceuticals NASDAQ:MIRA$1.22 -0.01 (-0.81%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.22 0.00 (-0.41%) As of 06/20/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.Q32 Bio NASDAQ:QTTB$1.55 -0.05 (-2.82%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.55 +0.00 (+0.06%) As of 06/20/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
